Khandaker M H, Kadhim S A, Ichim T E, Howson-Jan K, Chin J, Singhal S K
Department of Microbiology and Immunology, University of Western Ontario, London, Canada.
Anticancer Res. 2000 Jan-Feb;20(1A):183-9.
Reptimed is a novel, species-conserved, bone marrow-derived molecule which possesses anti-neoplastic activity. Previously, we established an orthotopic murine bladder tumor (MBT-2) model and reported accurate documentation of the presence and the extent of intravesical involvement of bladder tumor implants using magnetic resonance imaging (MRI) (1). Herein, we investigated the activity of exogenously administered Reptimed in the MBT-2 model.
Intravesicular and intraperitoneal administration of Reptimed concurrently with and following transurethral tumor cell implantation was performed and MBT-2 tumor response was assessed at several time points post tumor implant.
Serial MRI scans of Reptimed-treated mice at days 14 to 33 post tumor transplant revealed significant inhibition of bladder tumor growth with no significant tumor growth observed by MRI on day 33 post-implant. The corresponding histological examination of the whole mount bladder sections revealed similar inhibitory effects of Reptimed with respect to the topography and depth of intravesical tumor involvement. In contrast, control, untreated bladders revealed extensive exophytic tumors with deeply invasive transitional cell carcinoma.
These studies demonstrate the anti-tumor effect of Reptimed and highlight its importance as a potential therapy for cancer.
Reptimed是一种新型的、物种保守的、源自骨髓的分子，具有抗肿瘤活性。此前，我们建立了一种原位小鼠膀胱肿瘤（MBT-2）模型，并报告了使用磁共振成像（MRI）对膀胱肿瘤植入物膀胱内累及的存在和范围进行的准确记录（1）。在此，我们研究了在MBT-2模型中外源性给予Reptimed的活性。
在经尿道肿瘤细胞植入同时及之后进行Reptimed的膀胱内和腹腔内给药，并在肿瘤植入后的几个时间点评估MBT-2肿瘤反应。
在肿瘤移植后第14至33天对接受Reptimed治疗的小鼠进行的系列MRI扫描显示，膀胱肿瘤生长受到显著抑制，在植入后第33天通过MRI未观察到明显的肿瘤生长。对整个膀胱切片进行的相应组织学检查显示，Reptimed对膀胱内肿瘤累及的形态和深度具有类似的抑制作用。相比之下，未治疗的对照膀胱显示出广泛的外生性肿瘤，伴有深度浸润性移行细胞癌。
这些研究证明了Reptimed的抗肿瘤作用，并突出了其作为一种潜在癌症治疗方法的重要性。
